Literature DB >> 2645383

Tumor necrosis factor: still a promising agent.

E Frei1, D Spriggs.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645383     DOI: 10.1200/JCO.1989.7.3.291

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Tumor necrosis factor in benign and malign tissue of the kidney.

Authors:  K H Bichler; S Kleinknecht; H J Nelde; W L Strohmaier
Journal:  Urol Res       Date:  1991

4.  Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma.

Authors:  N Yoshida; S Ikemoto; K Narita; K Sugimura; S Wada; R Yasumoto; T Kishimoto; T Nakatani
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

5.  Augmented systemic immunity in mice implanted with tumor necrosis factor-alpha gene-transduced Meth-A-cells.

Authors:  S Fujii; Y Liu; H Neda; Y Itoh; Y Koshita; M Takahashi; N Watanabe; Y Kohgo; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1994-03

6.  Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines.

Authors:  N Suzuki; S Sekiya; I Sugano; T Kojima; H Yamamori; Y Takakubo
Journal:  Jpn J Cancer Res       Date:  1995-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.